Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06167161 · ClinicalTrials.gov registry record · NA
Clinical Investigation and Validation of a Self-fitted Air-conduction Hearing Aid
A NA study of Hearing Loss, sponsored by Concha.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT06167161: Completed NA study of Hearing Loss, sponsored by Concha.
NCT06167161 is a NA study of Hearing Loss that has completed, run by Concha. The registered enrollment target is 21 participants, below the 6,121-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06167161, a NA study of Hearing Loss, has completed, sponsored by Concha.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
Approximately 48 million people in the United States have hearing loss or hearing difficulties in noisy environments. Concha Inc. is working on introducing a wireless air-conduction hearing aid to the market, featuring a self-fitting feature. Self-fitting hearing aids have emerged in recent years as a potentially viable option towards addressing unmet hearing health care needs for millions of individuals who suffer from mild-to-moderate hearing loss. The purpose of this study is to evaluate the efficiency and reliability of the self-fitting strategy developed by Concha Inc.
Primary Outcome
A standardized measure of speech communication in noise, Quick Speech-in-Noise. (QuickSIN). Scores are clinically reported as SNR loss, the difference (in dB) between a listener's performance and that of normal-hearing adult controls. The SNR loss score is an indication of an individual's overall degree of difficulty understanding speech in noise. The greater the SNR loss the poorer the listener's ability is to hear in noise. The QuickSIN test manual provides adjective descriptors corresponding
Conditions Studied
Interventions
- DEVICE Hearing aid
Study Locations (2)
California
- San Jose State University - San Jose
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2023-05-30 |
| Phase | NA |
What the finished NCT06167161 record still lists
NCT06167161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 6,121-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which Hearing aid is the first listed.
NCT06167161 reports a single indexed study location in California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06167161 about?
NCT06167161 is a clinical study titled "Clinical Investigation and Validation of a Self-fitted Air-conduction Hearing Aid". Approximately 48 million people in the United States have hearing loss or hearing difficulties in noisy environments. Concha Inc. is working on introducing a wireless air-conduction hearing aid to the market, featuring a self-fitting feature. Self-fitting hearing aids have emerged in recent years as...
What is the current status of trial NCT06167161?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2023-01-30. Estimated completion is 2023-05-30.
What conditions does trial NCT06167161 study?
This clinical trial studies the following conditions: Hearing Loss.
What interventions are being tested in trial NCT06167161?
The interventions under investigation include: Hearing aid (DEVICE).
Who is sponsoring clinical trial NCT06167161?
This trial is sponsored by Concha, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06167161 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06167161's enrollment target sits among peer trials
21 56th of 58 higher than 3 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI